Can an inflamed fatty liver drive chronic low-grade systemic inflammation?

The claim that an inflamed fatty liver (metabolic dysfunction-associated steatohepatitis, or MASH/NASH) serves as a primary driver of systemic inflammation is strongly supported by clinical and mechanistic evidence. While simple fatty liver (steatosis) is relatively quiescent, the progression to an inflamed state marks a critical shift where the liver becomes a significant source of circulating inflammatory mediators.

Clinical and systemic evidence

Clinical studies consistently demonstrate that patients with MASH exhibit significantly higher serum levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) compared to those with simple steatosis or healthy controls.

• Cytokine spillover: Research using hepatic vein catheterization has identified a transhepatic gradient, proving that the inflamed liver actively exports these cytokines into the systemic circulation.
• Systemic markers: This "spillover" is associated with a 2- to 4-fold increase in systemic inflammatory markers, including C-reactive protein (CRP), which the liver produces in response to elevated IL-6.
• Population context: In older adults (e.g., age 60+), this hepatic contribution to the systemic "cytokine pool" accelerates "inflammaging," a state of chronic, sterile, low-grade inflammation that increases the risk for cardiovascular disease and type 2 diabetes.

Mechanistic explanations

The transition to systemic inflammation involves complex intrahepatic signaling pathways:

• Cellular activation: Lipotoxicity from saturated fatty acids and cholesterol activates the NLRP3 inflammasome and NF-κB pathways within hepatocytes and resident Kupffer cells.
• Specific mediators: TNF-α is primarily released by Kupffer cells triggered by gut-derived endotoxins (LPS) or damage-associated molecular patterns (DAMPs). IL-6 is subsequently produced by both hepatocytes and immune cells.
• Metabolic feedback: Once systemic, TNF-α interferes with insulin signaling by inducing serine phosphorylation of insulin receptor substrate-1 (IRS-1), which promotes peripheral insulin resistance and creates a feed-forward loop that worsens hepatic fat accumulation.

Bottom line

Inflamed fatty liver is not a localized condition; it acts as a metabolic hub that exports IL-6 and TNF-α into the bloodstream. This process drives chronic low-grade systemic inflammation, directly contributing to multi-organ metabolic dysfunction and increased cardiovascular risk.